HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.
HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $71.00 $92.00 | 8 | |
O antagonista dos receptores da angiotensina II pode ter impacto na função vascular e nas vias de sinalização relacionadas. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Outro antagonista dos receptores da angiotensina II, com potencial para afetar a pressão arterial e a angiogénese. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Inibe a HMG-CoA redutase, influenciando potencialmente os níveis de colesterol e a sinalização celular relacionada com a inflamação e a angiogénese. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Inibe múltiplas tirosina-quinases envolvidas na angiogénese, afectando potencialmente os processos em que a HRG-β3 poderia estar envolvida. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modula as respostas imunitárias e inibe a angiogénese, com potencial impacto nas vias relacionadas com a HRG-β3. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inibe as quinases RAF e outros receptores, podendo afetar a proliferação celular e a angiogénese. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Ativa a AMPK, influenciando potencialmente as vias metabólicas e o crescimento celular relacionados com a HRG-β3. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Inibe a tirosina quinase de Bruton, podendo afetar a sinalização das células B e as respostas imunitárias. |